In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Ovid Therapeutics (OVID – Research Report), with a price target of $7.00. The company’s shares closed last Monday at $3.32.
According to TipRanks.com, Higgins is a 4-star analyst with an average return of 6.2% and a 32.7% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Armata Pharmaceuticals, and Rhythm Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ovid Therapeutics with a $7.00 average price target.
Based on Ovid Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $11.38 million. In comparison, last year the company earned revenue of $6.91 million and had a GAAP net loss of $16.42 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ovid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.
Read More on OVID:
- Builders’ First Resource: Macro Tailwinds Propel the Stock
- Roku: Plenty of Positives, but Is Relatively Overvalued
- Deutsche Bank Pulls the Trigger on This High-Yield Dividend Stock
- Tractor Supply Stock: Satisfying Growth Record, Concerning Valuation
- Tesla (TSLA): New Sell Recommendation for This Technology Giant